TabsDetailsBasic DetailsDate Posted: Friday, June 3, 2016Status: CompleteMedical Product: Androgel, Axiron, Fortesta, Striant, Testim, intramuscular testosterone, methyltestosterone, testosterone, testosterone cypionate, testosterone enanthate, testosterone pellet, testosterone propionate, testosterone suspension, transdermal testosteroneDescription: Modular program-based one-time assessment of the incident use of testosterone products among members with pre-existing testosterone use and members with no pre-existing inclusions or exclusions. The query was run against the Mini-Sentinel Distributed Database (MSDD) for the time period of January 1, 2007 to May 31, 2013. Modular programs are adaptable standardized programs. Results were generated using Modular Program 3, version 1.0; click here for more information. Queries were distributed in March 2014. This report includes data from 18 Data Partners. If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance by sending an email requesting assistance to info@sentinelsystem.org. The information contained on this website is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Please read the disclaimer. Read More Deliverables (1)Mini-Sentinel Modular Program Report: Incident use of Testosterone Products among All Members and Members with Pre-Existing Testosterone UseAdditional InformationAdditional DetailsFDA Center: CDERTime Period: January 1, 2007 - May 31, 2013Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: All individuals with pre-existing testosterone useData Sources: Mini-Sentinel Distributed Database (MSDD)
